Affomix to Select mAbs for Kalgene Pharma | GenomeWeb

NEW YORK (GenomeWeb News) – Monoclonal antibody company Affomix said today it has signed an agreement with Kalgene Pharmaceuticals to select antibodies with potential diagnostic and therapeutic use in breast cancer.

Under the agreement, Branford, Conn.-based Affomix will use its Y2HExpress technology to generate antibodies against several proprietary targets selected by Kalgene.

Financial terms of the agreement have not been disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.